Generic Medicine Info
Indications and Dosage
Prophylaxis of exercise-induced asthma, Reversible airways obstruction
Adult: As metered-dose inhaler (100 mcg/dose): 1-2 inhalations as needed. Max: 8 inhalations daily. As soln (50 mcg/drop): 0.5 mL (10 drops or 500 mcg) up to 4 times daily.

Acute asthma
Adult: As metered-dose inhaler (100 mcg/dose): 1 inhalation as needed, if symptoms are not adequately controlled after 5 min, a 2nd dose may be given. As soln (50 mcg/drop): 0.5 mL (10 drops or 500 mcg), may require higher doses between 1-1.25 mL (20-25 drops or 1,000-1,250 mcg) in severe cases.
Child: 6-12 yr 22-36 kg/body wt: As soln (50 mcg/drop): 0.25-0.5 mL (5-10 drops or 250-500 mcg). May require higher doses up to 1 mL (20 drops or 1,000 mcg) in severe cases.

Acute bronchospasm
Adult: 2.5-5 mg tid. Max: 15 mg daily.
Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Special Precautions
Patient w/ severe asthma, underlying severe heart disease (e.g. ischaemic heart disease, severe organic heart disease, arrhythmia, severe heart failure), insufficiently controlled DM, recent MI, hyperthyroidism, phaeochromocytoma, and severe vascular disorder. Pregnancy and lactation.
Adverse Reactions
Hypokalaemia, hypersensitivity, nervousness, agitation, headache, dizziness, tremor, palpitations, myocardial ischaemia, tachycardia, arrhythmia, nausea, vomiting, hyperhidrosis, skin reactions (e.g. urticaria, rash, pruritus), myalgia, muscular weakness, muscle spasm, paradoxical bronchospasm, cough, throat irritation, increased systolic and decreased diastolic BP.
Monitoring Parameters
Monitor serum K levels.
Symptoms: Palpitation, tachycardia, tremor, HTN, hypotension, widening of pulse pressure, anginal pain, arrhythmias, flushing, metabolic acidosis. Management: Admin of tranquilisers, sedatives in severe cases; β-receptor blockers preferably β1-selective. Intensive therapy may be required.
Drug Interactions
Increased effect w/ β-adrenergics, anticholinergics, MAOIs, TCAs and xanthine derivatives (e.g. theophylline). Serious reduction in bronchodilation w/ β-blockers. May enhance susceptibility to CV effects w/ halothane, enflurane, and trichloroethylene.
Mechanism of Action: Fenoterol is a direct-acting sympathomimetic agent w/ predominant β-adrenoceptor stimulant activity largely selective for β2-receptors.
Onset: W/in a few min (inhalation).
Duration: Approx 3-5 hr (inhalation).
Absorption: Incompletely absorbed from the GI tract.
Distribution: Enters breast milk.
Metabolism: Undergoes extensive first-pass metabolism via sulfate conjugation
Excretion: Via urine and bile (mainly as inactive sulfate conjugate).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Fenoterol, CID=3343, https://pubchem.ncbi.nlm.nih.gov/compound/Fenoterol (accessed on Jan. 20, 2020)

Store below 30°C.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03CC04 - fenoterol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03AC04 - fenoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Anon. Fenoterol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/02/2016 .

Berotec. MIMS Indonesia. http://mims.com/indonesia. Accessed 10/02/2016 .

Buckingham R (ed). Fenoterol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2016 .

Disclaimer: This information is independently developed by MIMS based on Fenoterol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in